From Forbes magazine - November 23rd, 2020:
Here’s What You Need To Know About AstraZeneca’s Covid-19 Vaccine
Pharmaceutical giant AstraZeneca and its partner Oxford University released preliminary results from its phase 3 Covid-19 vaccine trials on Monday, which found that the company’s vaccine, which uses a genetically modified cold virus, is up to 90% effective. This makes AstraZeneca the third to announce preliminary data from its phase 3 trials, after Moderna and Pfizer released results from their phase 3 trials earlier this month. Both Moderna and Pfizer, whose vaccines use an mRNA platform, found their vaccines to be about 95% effective. The AstraZeneca/Oxford vaccine showed a somewhat lower efficacy, but is less expensive and poses fewer issues involved in distribution and administration.
A bit more:
The AstraZeneca-Oxford vaccine is a chimpanzee adenovirus-vectored vaccine. This means that the company took a virus that normally infects chimpanzees, and genetically modified to avoid any possible disease consequences in people. This modified virus carries a portion of the Covid-19 coronavirus called the “spike protein.” When the vaccine is delivered into human cells, it triggers an immune response against the spike protein, producing antibodies and memory cells that will be able to recognize the virus that causes Covid-19.
So we already know that vaccinated people have weaker immune systems and that the majority of coof cases are in people who have recieved more than one jab. Now this? Monkeypox anyone?
Leave a comment